ALK and non-small cell lung carcinoma: In another phase 3 trial, 343 patients with advanced ALK-positive non-squamous NSCLC were randomly assigned to receive crizotinib (250 mg/bid) or chemotherapy (pemetrexed or plus either cisplatin, or carboplatin).